Seer, Inc. (SEER) Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Sector: Laboratory Analytical Instruments
Industry: Biotechnology
Seer, Inc. NASDAQ:SEER Healthcare · Biotechnology
Mkt Cap $93.02M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 3
Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process
Seer announced that the Special Committee of its Board unanimously rejected two unsolicited acquisition proposals and that the company will remain an independent public company.
The Radoff-JEC Group (Bradley L. Radoff and Michael Torok) had offered $2.55 per share in cash plus a CVR on July 28, 2026, while Seer's own Chair and CEO Omid Farokhzad offered $2.45 per share in cash plus two CVRs on July 29, 2026.
The Committee concluded that both proposals undervalued Seer and its prospects, though the CEO being a bidder raises unusual governance questions around continued activist pressure.
• 3d ago AI analysis › Press Release
Seer to Report Third Quarter 2026 Financial Results on November 10, 2026
Seer, Inc. announced it will report Q3 2026 financial results on Tuesday, November 10, 2026.
Management will host a conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern, with a live webcast available on the company's investor site and an archived replay to follow.
This is a routine earnings-calendar notice with no financial figures or business updates.
• 11d ago AI analysis › Press Release ⚠ 1
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
Seer announced that Nanyang Technological University researchers will present early PRECISE-SG100K findings at the HUPO 2026 World Congress in Singapore, September 27 to October 1.
The study applied Seer's Proteograph Product Suite with mass spectrometry to deeply profile the plasma proteome of 10,000 participants within a Singapore cohort of over 100,000, with Seer citing a 7 to 10-fold increase in protein coverage depth versus direct plasma analysis.
Early proteogenomic and epidemiological signals reportedly show potential to accelerate biomarker discovery, reinforcing Seer's positioning in population-scale proteomics, though no commercial or financial results were disclosed.
• 1mo ago AI analysis › Press Release ⚠ 3
Seer Announces CFO Transition
David Horn, Seer's President, Chief Financial Officer and Treasurer, will depart the company effective October 1, 2026, to pursue a new opportunity at a private company.
Charles Endweiss, Seer's Vice President of Financial Planning & Analysis since January 2021, will assume the Treasurer, principal financial officer and principal accounting officer roles on the same effective date.
CEO Omid Farokhzad credited Horn's more than six years of service guiding the company and said Endweiss brings the financial expertise and deep understanding of the business critical to Seer's continued progress.
The same-day internal succession and Horn's public endorsement of the team and Seer's technology limit perceived disruption risk, though investors may watch for any shift in financial strategy under the new finance chief.
• 1mo ago AI analysis › Press Release ⚠ 2
Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
Seer's Proteograph Product Suite has now been used in more than 100 peer-reviewed publications by academic, government and industry researchers across three continents, six years after the approach was first described in Nature Communications.
Flagship studies include a Nature Genetics paper profiling more than 1,400 British South Asian participants that identified over 3,430 proteins not covered by leading affinity-based platforms, plus aging research drawing on more than 1,000 Baltimore Longitudinal Study of Aging participants.
CEO Omid Farokhzad framed the milestone as proof that deep, unbiased proteomics can scale to population-level cohorts, positioning Seer as a data foundation for AI-driven biological models.
The release carries no revenue or order figures, and Seer's products remain research-use only; additional Proteograph-enabled research will be presented at the HUPO World Congress in Singapore from September 27 to October 1.
• 1mo ago AI analysis › Press Release ⚠ 5
Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors
Activist investors Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of Seer, Inc., publicly called on director Meeta Gulyani to immediately resign from the board.
Their open letter argues Gulyani is unqualified, citing no prior public-company board experience, her 2023 departure from Merck KGaA, and the fact she has never purchased a Seer share despite the stock trading at a discount to net cash.
The letter also highlights Seer's collapse from a roughly $1.5 billion market cap in November 2021 to just over $100 million, a share-price decline of over 90% during her tenure.
It further criticizes the two-member Special Committee for refusing to explain its purpose and notes the activists' meeting to discuss their fourth acquisition proposal ended with Gulyani asking no questions — keeping governance pressure and takeover speculation on the micro-cap alive.
• 1mo ago AI analysis › Press Release ● Major ⚠ 4
Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
Radoff-JEC Group, owning 7.7% of Seer, demanded the board publicly acknowledge the company should be taken private and evaluate its $2.55/share acquisition offer.
The activist group criticized the Special Committee for "perfunctory" engagement and cited Q2 results showing revenue of $3.1 million and a $16.9 million net loss as evidence of the company's "abysmal" state.
The letter also attacked CEO Omid Farokhzad for optimistic commentary despite declining performance and noted he has sold over $103 million in shares since the IPO.
• 2mo ago AI analysis › Press Release ⚠ 3
Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
Seer reported Q2 revenue of $3.1 million, down 23% year-over-year, attributing the decline to macroeconomic headwinds and extended sales cycles.
Operating expenses fell 19% to $18.3 million, helping narrow the net loss to $16.9 million, while the company ended the quarter with a strong cash position of $209.5 million.
Management reaffirmed full-year 2026 revenue guidance of $16 million to $18 million and noted the repurchase of approximately 200,000 shares during the quarter.
• 2mo ago AI analysis › Press Release
Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
Seer announced that its management team will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston.
The presentation is scheduled for Wednesday, August 12, from 8:00 a.m. to 8:25 a.m. Eastern Time, with a live webcast available on the company's investor relations website.
An archived replay of the session will be accessible following the conclusion of the conference.
• 2mo ago AI analysis › Press Release
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026
Seer announced it will report financial results for the second quarter of 2026 on Tuesday, August 11, 2026.
Management will host a conference call to discuss the results beginning at 1:30 p.m. Pacific Time.
Live audio of the webcast will be available on the Investor section of Seer’s website, with an archived replay to follow.
• 2mo ago AI analysis › Press Release ● Critical ⚠ 2
Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
Seer confirmed receipt of two revised unsolicited acquisition proposals, one from the Radoff-JEC Group at $2.55 per share and another from CEO Dr. Omid Farokhzad at $2.45 per share.
Both proposals are non-binding and consist of cash plus contingent value rights, with the CEO's offer including two separate rights compared to the Radoff-JEC Group's single right.
The Special Committee of the Board will review both bids alongside other strategic alternatives, and the CEO's proposal letter will be filed in a Form 8-K.
• 3mo ago AI analysis › Press Release
Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting
Seer stockholders have voted to re-elect all seven of the company's director nominees to the Board of Directors, according to preliminary results from the 2026 Annual Meeting.
The outcome reflects stockholder confidence in the Board as the company continues to focus on disciplined execution of its strategy, including scaling platform commercialization and advancing its innovation pipeline.
Seer expects to report final certified voting results on a Form 8-K filing with the SEC.
• 3mo ago AI analysis › Press Release
Radoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc.
businesswire.com • 3mo ago Press Release ⚠ 3
Radoff-JEC Group Announces That Glass Lewis Has Joined ISS in Supporting its Case for Change at Seer, Inc.
The Radoff-JEC Group, which owns approximately 7.7% of Seer, announced that Glass Lewis has joined ISS in supporting its proxy contest, recommending shareholders vote for two activist nominees and withhold support for incumbent directors McGuire and Nishar.
Glass Lewis cited Seer’s prolonged underperformance, continued operating losses, and uncertain path to commercial scale as justification for board refreshment, while also advising a vote against the recently adopted NOL pill.
The activists are urging stockholders to vote the white proxy card prior to the July 28 annual meeting to elect independent directors capable of evaluating strategic alternatives.
• 3mo ago AI analysis › Press Release ● Major ⚠ 1
Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
Seer's independent board committee unanimously rejected a non-binding proposal from CEO Omid Farokhzad to acquire all outstanding Class A shares.
The offer of $2.45 per share in cash plus two contingent value rights was deemed to undervalue the company and fail to reflect its long-term growth prospects.
The committee, composed of directors Meeta Gulyani and Nicolas Roelofs, consulted with independent advisors before determining the proposal was not in stockholders' best interests.
• 3mo ago AI analysis › Press Release ● Major ⚠ 4
Radoff-JEC Group Announces ISS’ Support of its Case for Change at Seer, Inc.
Radoff-JEC Group, which owns approximately 7.7% of Seer, announced that Institutional Shareholder Services (ISS) recommends voting for its three director nominees and withholding support from current management, including CEO Omid Farokhzad.
The ISS report criticized the company for losing over 95% of its market cap since its 2020 IPO and stated that profitability is not expected to be achieved before 2031.
ISS also questioned the board's independence and highlighted contradictions regarding the evaluation of take-private offers, suggesting the board's account is not supported by the facts.
• 3mo ago AI analysis › Press Release ● Major ⚠ 2
Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight
Seer's Board of Directors issued a letter to shareholders urging them to vote 'FOR' its seven nominees on the BLUE proxy card ahead of the July 28 Annual Meeting, directly countering the dissident Radoff-JEC Group.
The company defended its performance, stating that cash burn has fallen 36% since 2022 and operating expenses declined approximately 19% year-over-year in 2025, rebutting activist claims of value destruction.
Management characterized the proxy contest as an attempt to install a short-term agenda focused on selling the company and stripping cash, arguing that the current strategy maximizes long-term value creation.
• 3mo ago AI analysis › Press Release ● Major ⚠ 5
The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company’s Blatant Rewriting of History
The Radoff-JEC Group, owning approximately 7.7% of Seer, issued a letter to stockholders urging them to vote for three independent director nominees ahead of the July 28 annual meeting.
The activist group claims the current Board has overseen a 97% decline in total shareholder return since the IPO, cumulative losses exceeding $465 million, and questionable independence among several directors.
Radoff-JEC argues that an objective strategic review is necessary to maximize value, noting it has submitted acquisition proposals offering premiums of 33% to 42% which the Board rejected without engagement.
• 3mo ago AI analysis › Press Release ● Major ⚠ 3
Seer Board of Directors Issues Letter to Shareholders Demonstrating the Strength and Experience of Seer’s Director Nominees
Seer's Board of Directors issued a letter to shareholders urging them to vote 'FOR' the company's seven director nominees on the BLUE proxy card ahead of the July 28, 2026 Annual Meeting.
The communication serves as a defense against activists Bradley Radoff and Michael Torok, who are attempting to replace CEO Omid Farokhzad, Chair, and directors Terrance McGuire and Dipchand (Deep) Nishar.
The Board contends that the activist nominees lack the necessary proteomics and life sciences experience and argues that the activists' primary goal is to strip the company of its cash.
• 3mo ago AI analysis › Press Release ● Major ⚠ 2
The Radoff-JEC Group Responds to Chairman and CEO Omid Farokhzad, M.D.’s Proposal to Acquire Seer, Inc.
The Radoff-JEC Group, owning 7.7% of Seer, expressed support for selling the company to the highest bidder and criticized the board for rejecting three prior acquisition proposals while quickly forming a Special Committee for the CEO's offer.
The activist group noted that its rejected offer included an identical $2.45 per share cash component but superior contingent value rights compared to the CEO's July 1 proposal.
Shareholders are urged to vote for three independent nominees at the July 28 annual meeting to ensure a credible strategic review process aimed at maximizing value for all stockholders.
• 3mo ago AI analysis › Press Release ⚠ 2
Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential
Seer filed an investor presentation ahead of its July 28 annual meeting, reporting a 36% reduction in annual cash burn since 2022 and a 62% CAGR in installed base since 2021.
The company emphasized a strong balance sheet with approximately $220 million in cash and no debt, while highlighting a $23 billion TAM opportunity by 2034.
The Board urged shareholders to vote for the seven incumbent director nominees, rejecting activist proposals from Bradley Radoff and Michael Torok as lacking credibility and actionable ideas.
• 3mo ago AI analysis › Press Release ● Critical ⚠ 2
Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
Seer announced it received an unsolicited, non-binding proposal from its own CEO and Chairman, Omid Farokhzad, to acquire all outstanding Class A shares for $2.45 per share in cash plus contingent value rights.
The Board will form a Special Committee of independent directors to evaluate the proposal and other alternatives, retaining Perella Weinberg Partners as financial advisor and Wilson Sonsini as legal counsel.
This internal buyout proposal creates a binary outcome for shareholders, with the Special Committee tasked with determining the best course of action for the company.
• 4mo ago AI analysis › Press Release ● Major
Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics
Seer announced that the European Patent Office has decided to maintain its patent EP4056263 covering particle-based enrichment, successfully defeating an opposition seeking revocation.
Concurrently, the U.S. International Trade Commission instituted an investigation into Nanomics Biotechnology regarding the alleged infringement of five Seer patents, targeting Nanomics' Proteonano kits and workstations.
CEO Omid Farokhzad emphasized that these developments validate the strength of Seer's IP portfolio and its commitment to vigorously defending its proprietary technology.
• 4mo ago AI analysis › Press Release ● Major ⚠ 5
The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change
The Radoff-JEC Group, owning approximately 7.7% of Seer, issued a presentation urging shareholders to vote out the current Board of Directors at the July 28 annual meeting, citing a 97% decline in share price and over $310 million in cash burn since the IPO.
The activists accuse Chair and CEO Omid Farokhzad of selling over $103 million in shares while the company's market cap fell to $92.4 million and criticize the board for adopting a poison pill to entrench management.
Radoff-JEC nominated Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini as independent directors, arguing they are needed to stop further value destruction and conduct a strategic review.
• 4mo ago AI analysis › Press Release
Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening
Seer and Korea University presented preliminary data at ASMS 2026 demonstrating the Proteograph platform's ability to enable AI-driven multi-cancer screening through deep plasma proteomics.
The analysis covered more than 5,500 plasma samples across ten major cancer types, achieving coverage of more than 14,000 protein groups per sample with high reproducibility.
This ongoing collaboration plans to scale to more than 20,000 clinical samples, utilizing an ID-Free AI framework to uncover biological patterns for future screening strategies.
• 4mo ago AI analysis › Press Release ⚠ 3
The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction
The Radoff-JEC Group, owning 7.7% of Seer Inc., issued a public statement criticizing Chairman and CEO Omid Farokhzad for a 97% share price decline since the 2020 IPO.
The group is soliciting stockholder votes to elect three independent directors—Howard Berman, Joshua Horowitz, and Luis Rinaldini—at the July 28, 2026 Annual Meeting.
The release urges shareholders to vote against incumbent directors Farokhzad, Terrance McGuire, and Deep Nishar, citing a history of value destruction across Farokhzad’s previous ventures.
• 4mo ago AI analysis › Press Release ⚠ 2
Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign
Seer’s Board issued a letter to shareholders urging support for its seven director nominees at the July 28 Annual Meeting, framing the vote as a choice between long-term scientific execution and a short-term activist campaign by Bradley Radoff and Michael Torok.
The Board highlighted operational momentum, citing a 67% expansion in installed base, 69% growth in consumable kit volumes, and a 19.3% year-over-year decline in operating expenses in 2025.
Financially, Seer has repurchased approximately 13.2 million shares since 2024 at an average price of $1.86, reducing net diluted shares by ~15%, and announced a new $25 million buyback authorization in February 2026.
• 4mo ago AI analysis › Press Release ⚠ 3
Seer Files Definitive Proxy Materials and Mails Letter to Stockholders
Seer filed definitive proxy materials for its July 28, 2026 Annual Meeting, urging stockholders to vote for its seven director nominees on the BLUE proxy card to defeat a proxy contest launched by activist investors Bradley Radoff and Michael Torok.
The Board rejected Radoff and Torok’s unsolicited acquisition proposal of approximately $141 million, stating it significantly undervalues the company given its $220 million in cash and investments and long-term growth potential in proteomics.
Seer highlighted operational discipline, noting operating expenses dropped from $22.8 million in Q1 2025 to $18.2 million in Q1 2026, and reaffirmed its strategy of returning capital via share buybacks, having repurchased $24.5 million worth of shares since 2024.
• 4mo ago AI analysis › Press Release ⚠ 2
Seer Files ITC Complaint Against Nanomics
Seer filed a complaint with the U.S. International Trade Commission against Nanomics Biotechnology, alleging infringement of five patents related to nanoparticle protein enrichment.
The ITC action seeks an exclusion order to bar Nanomics' Proteonano kits and workstations from entering the United States, building on a federal district court suit filed in May 2026.
Brigham and Women's Hospital joined the complaint as a co-complainant, reinforcing Seer's claim that Nanomics' products threaten the integrity of the proteomics field.
• 5mo ago AI analysis › Press Release ⚠ 4
The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders
Activist group Radoff-JEC, owning 7.8% of Seer, filed a preliminary proxy statement to elect three new directors and is urging the board to accept its $2.40 per share acquisition offer.
The offer represents a 42% premium to the unaffected share price and includes a contingent value right for stockholders to receive 80% of net proceeds from asset sales.
The activist accuses the board and CEO Omid Farokhzad of breaching fiduciary duties by rejecting the bids without engagement, citing Seer’s -97% total shareholder return since IPO and declining revenue.
• 5mo ago AI analysis › Press Release
Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026
Seer will showcase its AI-driven multi-cancer screening approach and next-generation proteomics tools at the ASMS 2026 conference in San Diego.
The company will preview findings from a collaboration with Korea University analyzing over 20,000 clinical plasma samples for multi-cancer screening.
Seer will also introduce Radiant DIA, a new data processing engine designed to significantly reduce runtime for large-scale proteomics studies.
• 5mo ago AI analysis › Press Release ⚠ 2
Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group
Seer’s Board of Directors unanimously rejected a further revised unsolicited proposal from the Radoff-JEC Group to acquire the company for $2.40 per share in cash plus a contingent value right.
The Board determined the offer significantly undervalues Seer and fails to reflect its long-term growth prospects, noting the implied equity value is meaningfully below the sum of Seer’s current cash, cash equivalents, and investments.
This rejection follows a similar dismissal of a materially identical proposal on April 27, 2026, with Perella Weinberg Partners serving as financial advisor and Wilson Sonsini Goodrich & Rosati as legal counsel.
• 5mo ago AI analysis › Press Release ● Major
The Radoff-JEC Group Submits its Third Non-Binding Proposal to Acquire Seer, Inc.
businesswire.com • 5mo ago Press Release ● Major
Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
globenewswire.com • 5mo ago Press Release ● Major
Seer Files Patent Infringement Lawsuit Against Nanomics
globenewswire.com • 5mo ago Press Release
Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer
globenewswire.com • 5mo ago Press Release
Seer to Report First Quarter 2026 Financial Results on May 13, 2026
Seer announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026.
Company management will host a conference call beginning at 1:30 p.m. Pacific Time to discuss the results.
A live webcast and subsequent archived replay will be accessible via the Investor section of the Seer website.
• 6mo ago AI analysis › Press Release ● Major ⚠ 3
The Radoff-JEC Group Responds to Seer, Inc.’s Rejection of April 24th Acquisition Proposal
The Radoff-JEC Group, which owns approximately 7.6% of Seer, publicly criticized the Board for rejecting its non-binding acquisition proposal of $2.35 per share in cash plus a contingent value right.
The activists argued that the rejection ignores a 39% premium to the unaffected stock price and cited Seer's track record of over $465 million in cumulative losses and a 90% share price decline since IPO.
Radoff-JEC confirmed it will nominate three independent directors—Howard H. Berman, Joshua S. Horowitz, and Luis E. Rinaldini—at the upcoming annual meeting to force a strategic review.
• 6mo ago AI analysis › Press Release ● Major ⚠ 2
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
Seer’s Board of Directors unanimously rejected a revised unsolicited proposal from the Radoff-JEC Group to acquire all outstanding Class A common stock for $2.35 per share in cash plus a contingent value right.
The Board concluded that the proposal significantly undervalues the company, noting the implied equity value is materially below the sum of Seer’s current cash, cash equivalents, and investments.
The Corporate Governance and Nominating Committee will review the director nominees submitted by the Radoff-JEC Group, with a formal recommendation to be included in the definitive proxy statement for the upcoming Annual Meeting.
• 6mo ago AI analysis › Press Release
The Radoff-JEC Group Submits Improved Non-Binding Proposal to Acquire Seer, Inc.
businesswire.com • 6mo ago Press Release
Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group
globenewswire.com • 6mo ago Press Release
The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.
businesswire.com • 6mo ago Press Release
Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples
globenewswire.com • 6mo ago Press Release ● Major
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
globenewswire.com • 7mo ago Press Release
The Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs
businesswire.com • 7mo ago Press Release ● Major
Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
globenewswire.com • 8mo ago Press Release ● Major
Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook
globenewswire.com • 8mo ago Press Release ● Major
The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change
businesswire.com • 8mo ago Press Release
Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
globenewswire.com • 8mo ago Press Release
Seer to Participate in the TD Cowen 46th Annual Health Care Conference
globenewswire.com • 8mo ago Press Release ● Major
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
globenewswire.com • 8mo ago 
